Lupin acquires five brands from Menarini

Strengthens its position and key therapy portfolio in India

Lupin has signed an agreement to acquire five legacy brands in strategic therapy areas — gastroenterology, urology and anti-infectives from Menarini (A Menarini India and A Menarini Asia-Pacific Holdings), along with the associated trademark rights. The brands are Piclin (Picosulphate Sodium), Menoctyl (Otilonium Bromide), Sucramal O (Sucralfate + Oxetacaine), Pyridium (Phenazopyridine) and Distaclor (Cefaclor).


Lupin has been exclusively marketing these brands in the Indian market since July 2021 under a distribution and promotion agreement with A Menarini India. This strategic acquisition for the Indian market marks a significant step forward for Lupin as it continues to expand its presence in India. These legacy brands help Lupin further enhance its diverse portfolio and solidify its position as a leading pharmaceutical organization in India.

Nilesh Gupta, MD, Lupin said, “This acquisition aligns well with our strategic goal to broaden our presence in the Indian market. By offering a comprehensive range of products, we aim to deliver even greater value to our stakeholders and the communities we serve.”

“Growing urbanisation and dietary changes are driving the demand for gastrointestinal and urology treatments in India,” said Rajeev Sibal, President – India Region Formulations, Lupin. “This acquisition strengthens our presence in India and bolsters our therapy pipeline. At Lupin, we are committed to empowering healthcare professionals in managing the increasing disease burden and improving the lives of patients significantly.”

“Lupin has been successfully marketing the scope brands for Menarini since 2021, which has been a testament to our evolved collaboration. I am happy that Lupin will now carry forward its legacy with full trademark ownership. For Menarini, this transaction further signals our continued commitment to nurture and expand our Dermatology and Aesthetics portfolio and business. Menarini is a top 10 multi-national company in this therapeutic area in India and has witnessed strong organic and inorganic growth,” said Girisan Kariangal, MD, Menarini India.



Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.


Related Articles

Back to top button